Sara Rachelle Schoenfeld, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Scleroderma, Systemic | 3 | 2017 | 346 | 1.190 |
Why?
|
| Polymyalgia Rheumatica | 1 | 2018 | 52 | 0.610 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2017 | 940 | 0.560 |
Why?
|
| Dermatomyositis | 1 | 2020 | 259 | 0.560 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 667 | 0.510 |
Why?
|
| Arthritis, Psoriatic | 1 | 2018 | 219 | 0.500 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2018 | 3781 | 0.380 |
Why?
|
| Immunologic Factors | 1 | 2020 | 1596 | 0.370 |
Why?
|
| Hypertension, Pulmonary | 1 | 2017 | 1605 | 0.260 |
Why?
|
| Venous Thrombosis | 1 | 2016 | 1321 | 0.260 |
Why?
|
| Antirheumatic Agents | 1 | 2015 | 1381 | 0.250 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2019 | 2171 | 0.240 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 3251 | 0.220 |
Why?
|
| Pulmonary Embolism | 1 | 2016 | 2599 | 0.200 |
Why?
|
| Adrenal Insufficiency | 1 | 2024 | 195 | 0.190 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2024 | 180 | 0.190 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2020 | 224 | 0.160 |
Why?
|
| Atherosclerosis | 1 | 2013 | 3433 | 0.140 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 13677 | 0.130 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 426 | 0.130 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2017 | 159 | 0.130 |
Why?
|
| Cause of Death | 2 | 2017 | 3721 | 0.130 |
Why?
|
| British Columbia | 1 | 2016 | 240 | 0.130 |
Why?
|
| Prednisone | 1 | 2020 | 1567 | 0.130 |
Why?
|
| Pituitary Neoplasms | 1 | 2024 | 1322 | 0.120 |
Why?
|
| Respiratory Function Tests | 1 | 2017 | 1695 | 0.100 |
Why?
|
| Chest Pain | 1 | 2019 | 1101 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 2257 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2024 | 6004 | 0.090 |
Why?
|
| Cardiovascular Diseases | 2 | 2017 | 15662 | 0.090 |
Why?
|
| Propensity Score | 2 | 2017 | 1969 | 0.090 |
Why?
|
| Glucocorticoids | 1 | 2020 | 2167 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 6316 | 0.090 |
Why?
|
| Cohort Studies | 5 | 2024 | 41753 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2021 | 4754 | 0.080 |
Why?
|
| Echocardiography | 2 | 2019 | 5047 | 0.070 |
Why?
|
| Aged | 7 | 2024 | 171502 | 0.070 |
Why?
|
| Middle Aged | 9 | 2024 | 223487 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2019 | 3474 | 0.070 |
Why?
|
| Female | 11 | 2024 | 397187 | 0.070 |
Why?
|
| Humans | 18 | 2024 | 768171 | 0.070 |
Why?
|
| Male | 11 | 2024 | 364731 | 0.070 |
Why?
|
| Adult | 7 | 2024 | 223646 | 0.060 |
Why?
|
| Neoplasms | 3 | 2024 | 22371 | 0.060 |
Why?
|
| Synovitis | 1 | 2024 | 217 | 0.050 |
Why?
|
| Musculoskeletal System | 1 | 2024 | 188 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3115 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3238 | 0.050 |
Why?
|
| Mass Screening | 1 | 2017 | 5458 | 0.050 |
Why?
|
| Risk | 1 | 2013 | 9613 | 0.040 |
Why?
|
| Intubation | 1 | 2020 | 140 | 0.040 |
Why?
|
| Respiratory Therapy | 1 | 2020 | 125 | 0.040 |
Why?
|
| Melanoma | 1 | 2018 | 5706 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 59626 | 0.040 |
Why?
|
| Arthritis | 1 | 2024 | 684 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 5863 | 0.040 |
Why?
|
| Comorbidity | 1 | 2013 | 10590 | 0.040 |
Why?
|
| Cardiac Tamponade | 1 | 2019 | 175 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 39354 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2021 | 549 | 0.040 |
Why?
|
| Pericardial Effusion | 1 | 2019 | 246 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 610 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2024 | 1841 | 0.030 |
Why?
|
| Prevalence | 1 | 2013 | 15869 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2024 | 1238 | 0.030 |
Why?
|
| Arthralgia | 1 | 2019 | 459 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2016 | 24318 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2020 | 2661 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 13586 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2018 | 54924 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 20762 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 10397 | 0.030 |
Why?
|
| Inpatients | 1 | 2021 | 2566 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2021 | 3072 | 0.020 |
Why?
|
| Massachusetts | 1 | 2021 | 8890 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2020 | 3080 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8542 | 0.020 |
Why?
|
| Boston | 1 | 2020 | 9374 | 0.020 |
Why?
|
| Weight Loss | 1 | 2019 | 2721 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 6792 | 0.020 |
Why?
|
| Heart | 1 | 2020 | 4446 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2020 | 12466 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 13013 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2024 | 81760 | 0.010 |
Why?
|
| Disease Progression | 1 | 2020 | 13668 | 0.010 |
Why?
|
| Survival Rate | 1 | 2017 | 12840 | 0.010 |
Why?
|
| Hospitalization | 1 | 2021 | 10840 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8747 | 0.010 |
Why?
|
| Incidence | 1 | 2017 | 21538 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2021 | 65379 | 0.010 |
Why?
|
| Young Adult | 1 | 2020 | 60066 | 0.010 |
Why?
|